Switch theme
Sign up to access all valuation multiples
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
1998
34
Last FY Revenue $0.5M
Last FY EBITDA -$12.6M
-$2.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Epigenomics achieved revenue of $0.5M and an EBITDA of -$12.6M.
Epigenomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Epigenomics valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.5M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.4M | XXX | XXX | XXX |
| Gross Margin | XXX | 75% | XXX | XXX | XXX |
| EBITDA | XXX | -$12.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -2314% | XXX | XXX | XXX |
| EBIT | XXX | -$14.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | -2651% | XXX | XXX | XXX |
| Net Profit | XXX | -$13.5M | XXX | XXX | XXX |
| Net Margin | XXX | -2479% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Epigenomics's stock price is EUR 1 (or $1).
Epigenomics has current market cap of EUR 0.9M (or $1.0M), and EV of -EUR 2.4M (or -$2.7M).
See Epigenomics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$2.7M | $1.0M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Epigenomics has market cap of $1.0M and EV of -$2.7M.
Epigenomics's trades at -4.9x EV/Revenue multiple, and 0.2x EV/EBITDA.
Equity research analysts estimate Epigenomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Epigenomics's P/E ratio is not available.
See valuation multiples for Epigenomics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.0M | XXX | $1.0M | XXX | XXX | XXX |
| EV (current) | -$2.7M | XXX | -$2.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | -4.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 0.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEpigenomics's revenue per employee in the last FY averaged $16K, while opex per employee averaged $0.4M for the same period.
Epigenomics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Epigenomics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Epigenomics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -2314% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $16K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 886% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1276% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2727% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Epigenomics acquired XXX companies to date.
Last acquisition by Epigenomics was XXXXXXXX, XXXXX XXXXX XXXXXX . Epigenomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Epigenomics founded? | Epigenomics was founded in 1998. |
| Where is Epigenomics headquartered? | Epigenomics is headquartered in Germany. |
| How many employees does Epigenomics have? | As of today, Epigenomics has 34 employees. |
| Is Epigenomics publicy listed? | Yes, Epigenomics is a public company listed on FRA. |
| What is the stock symbol of Epigenomics? | Epigenomics trades under ECX ticker. |
| When did Epigenomics go public? | Epigenomics went public in 2014. |
| Who are competitors of Epigenomics? | Similar companies to Epigenomics include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Epigenomics? | Epigenomics's current market cap is $1.0M |
| Is Epigenomics profitable? | Yes, Epigenomics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
